Figure 2.

The simultaneous expression levels of TIM‐3 and CD39 had no significant difference in PD‐1⁺ CD4⁺ cells of COVID‐19 patients and healthy individuals. PBMCs were stained with CD4‐FITC, PD‐1‐PerCp‐Cy5.5, CD39‐PE, and TIM‐3‐APC conjugated monoclonal antibodies and analyzed with BD FACSCalibur flow cytometer. PD‐1⁺ CD4⁺ T cells were initially gated from the lymphocyte population to analyze the obtained graphs, and then the simultaneous expression levels of CD39 and TIM‐3 markers were determined in the PD‐1⁺ CD4⁺ T cell populations. (A) the healthy individuals; (B) the moderate/severe patients; (C) the critical patients. PBMC, peripheral blood mononuclear cell